Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0455 Transporter Info
Gene Name	SLC6A3
Transporter Name	Sodium-dependent dopamine transporter
Gene ID	6531
UniProt ID	Q01959

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Butyrates inhibits the reaction Cocaine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cocaine binds to SLC6A3 protein			[83]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cocaine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Cocaine inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Cocaine inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Cocaine inhibits the reaction Dopamine results in increased activity of SLC6A3 protein			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Cocaine inhibits the reaction Melitten results in increased localization of SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Cocaine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Cocaine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Cocaine inhibits the reaction SLC6A3 protein results in increased transport of phenethylamine			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Cocaine inhibits the reaction SLC6A3 protein results in increased uptake of 4-(4-(dimethylamino)phenyl)-1-methylpyridinium			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Cocaine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Cocaine promotes the reaction (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester binds to SLC6A3 protein			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Cocaine results in decreased expression of SLC6A3 mRNA			[86]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Cocaine results in increased expression of SLC6A3 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	SLC6A3 gene polymorphism results in increased susceptibility to Cocaine			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	SLC6A3 protein polymorphism affects the susceptibility to Cocaine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	SLC6A3 protein polymorphism affects the susceptibility to Cocaine which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Butyrates inhibits the reaction Mazindol inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Mazindol inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Mazindol results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A3 gene polymorphism affects the susceptibility to Modafinil			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Fluoxetine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fluoxetine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Fluoxetine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Methylphenidate co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Methylphenidate inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Methylphenidate inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Methylphenidate inhibits the reaction SLC6A3 protein mutant form results in increased export of Dopamine			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Methylphenidate inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Methylphenidate results in decreased expression of SLC6A3 protein			[103]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	SLC6A3 3' UTR polymorphism affects the susceptibility to Methylphenidate			[70]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Valproic Acid results in increased methylation of SLC6A3 gene			[115]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Amphetamine affects the localization of SLC6A3 protein			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Amphetamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Amphetamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Amphetamine co-treated with Zinc results in decreased localization of SLC6A3 protein			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Amphetamine inhibits the reaction SLC6A3 protein mutant form results in increased export of Dopamine			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Amphetamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Amphetamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Amphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC6A3 3' UTR polymorphism affects the susceptibility to Amphetamine			[70]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC6A3 3' UTR polymorphism results in decreased susceptibility to Amphetamine			[71]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	SLC6A3 protein results in increased susceptibility to Amphetamine			[71]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	SOD1 protein inhibits the reaction Amphetamine results in decreased expression of SLC6A3 protein			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Methamphetamine results in decreased activity of SLC6A3 protein			[99]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Methamphetamine results in decreased expression of SLC6A3 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A3 3' UTR polymorphism results in increased susceptibility to Methamphetamine			[101]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A3 protein affects the abundance of Methamphetamine			[102]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC6A3 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Citalopram inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 protein polymorphism affects the susceptibility to Citalopram			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein polymorphism affects the susceptibility to Citalopram which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dextroamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Dextroamphetamine results in decreased activity of SLC6A3 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-fluoroamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Amphetamine inhibits the reaction SLC6A3 protein mutant form results in increased export of Dopamine			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Amphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Benztropine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	bisindolylmaleimide I inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Bupropion inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Bupropion inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Bupropion inhibits the reaction SLC6A3 protein mutant form results in decreased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Bupropion inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Bupropion promotes the reaction SLC6A3 protein results in increased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Butyrates inhibits the reaction Cocaine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Butyrates inhibits the reaction Mazindol inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Citalopram inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	Cocaine inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	Cocaine inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation19	Cocaine inhibits the reaction Dopamine results in increased activity of SLC6A3 protein			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation20	Cocaine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation21	decamethrin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[35]
Regulation Mechanism				Transcription Factor Info
DT Modulation22	Dextroamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation23	Dopamine affects the localization of SLC6A3 protein			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation24	Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation25	Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation26	Dopamine results in increased activity of SLC6A3 protein			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation27	Fluoxetine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation28	Ibogaine inhibits the reaction SLC6A3 protein mutant form results in decreased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation29	Ibogaine promotes the reaction SLC6A3 protein results in increased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation30	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation31	Ketamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation32	LRRK2 mutant form results in increased susceptibility to Dopamine co-treated with SLC6A3 protein			[91]
Regulation Mechanism				Transcription Factor Info
DT Modulation33	Mazindol inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation34	Melitten inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation35	Methylphenidate inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation36	Methylphenidate inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation37	Methylphenidate inhibits the reaction SLC6A3 protein mutant form results in increased export of Dopamine			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation38	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation39	Methylphenidate inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation40	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation41	Nomifensine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation42	para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation43	Permethrin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[35]
Regulation Mechanism				Transcription Factor Info
DT Modulation44	SLC6A3 protein mutant form results in decreased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation45	SLC6A3 protein mutant form results in increased export of Dopamine			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation46	SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation47	SLC6A3 protein polymorphism affects the susceptibility to Bupropion which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation48	SLC6A3 protein polymorphism affects the susceptibility to Citalopram which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation49	SLC6A3 protein polymorphism affects the susceptibility to Cocaine which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation50	SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation51	SLC6A3 protein polymorphism affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation52	SLC6A3 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation53	SLC6A3 protein results in increased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation54	SLC6A3 protein results in increased susceptibility to Dopamine			[92]
Regulation Mechanism				Transcription Factor Info
DT Modulation55	SLC6A3 protein results in increased transport of Dopamine			[93]
Regulation Mechanism				Transcription Factor Info
DT Modulation56	SLC6A3 protein results in increased uptake of Dopamine			[35]
Regulation Mechanism				Transcription Factor Info
DT Modulation57	SNCA protein affects the localization of SLC6A3 protein which affects the uptake of Dopamine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation58	Sulpiride inhibits the reaction Dopamine affects the localization of SLC6A3 protein			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation59	Sulpiride inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation60	vanoxerine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation61	Wortmannin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Bupropion co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Bupropion inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS mRNA			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Bupropion inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Bupropion inhibits the reaction SLC6A3 protein mutant form results in decreased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Bupropion inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Bupropion promotes the reaction SLC6A3 protein results in increased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Bupropion results in increased expression of SLC6A3 protein			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC6A3 protein polymorphism affects the susceptibility to Bupropion			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC6A3 protein polymorphism affects the susceptibility to Bupropion which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in increased expression of SLC6A3 mRNA			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in increased expression of SLC6A3 mRNA			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A3 protein results in increased susceptibility to Rotenone			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Amphetamine co-treated with Zinc results in decreased localization of SLC6A3 protein			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Zinc results in decreased activity of SLC6A3 protein			[46]
Regulation Mechanism				Transcription Factor Info
1-Methyl-4-phenylpyridinium	13 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium inhibits the reaction (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester binds to SLC6A3 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	1-Methyl-4-phenylpyridinium results in decreased expression of SLC6A3 protein			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Curcumin inhibits the reaction 1-Methyl-4-phenylpyridinium results in decreased expression of SLC6A3 protein			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Mazindol results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Nomifensine results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC6A3 protein affects the susceptibility to 1-Methyl-4-phenylpyridinium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC6A3 protein results in increased susceptibility to 1-Methyl-4-phenylpyridinium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	SNCA protein affects the reaction SLC6A3 protein results in increased susceptibility to 1-Methyl-4-phenylpyridinium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	SNCA protein mutant form promotes the reaction SLC6A3 protein results in increased susceptibility to 1-Methyl-4-phenylpyridinium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	vanoxerine results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium inhibits the reaction (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester binds to SLC6A3 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester binds to SLC6A3 protein			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cocaine promotes the reaction (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester binds to SLC6A3 protein			[60]
Regulation Mechanism				Transcription Factor Info
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone which affects the uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to and results in decreased activity of SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Melitten inhibits the reaction 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
4-fluoroamphetamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-fluoroamphetamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-fluoroamphetamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	4-fluoroamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
4-methoxymethamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methoxymethamphetamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-methoxymethamphetamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
4-methylaminorex	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-methylaminorex results in decreased activity of SLC6A3 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein results in increased uptake of 4-methylaminorex			[64]
Regulation Mechanism				Transcription Factor Info
5-(2-aminopropyl)benzofuran	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
Allura Red AC Dye	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with quinoline yellow co-treated with Allura Red AC Dye co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
Aluminum Hydroxide	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aluminum Hydroxide promotes the reaction BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Aluminum Hydroxide results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Aluminum Hydroxide results in increased expression of SLC6A3 protein			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Coconut Oil inhibits the reaction Aluminum Hydroxide promotes the reaction BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Coconut Oil inhibits the reaction Aluminum Hydroxide results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Thimerosal co-treated with Aluminum Hydroxide results in increased expression of SLC6A3 protein			[68]
Regulation Mechanism				Transcription Factor Info
Asbestos, Crocidolite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Asbestos, Crocidolite results in decreased methylation of SLC6A3 gene			[73]
Regulation Mechanism				Transcription Factor Info
azo rubin S	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with quinoline yellow co-treated with Allura Red AC Dye co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with Tartrazine co-treated with ponceau 4R co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
Benzo(a)pyrene	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC6A3 3' UTR			[74]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene affects the methylation of SLC6A3 intron			[75]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Benzo(a)pyrene results in increased methylation of SLC6A3 5' UTR			[74]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Benzo(a)pyrene results in increased methylation of SLC6A3 promoter			[74]
Regulation Mechanism				Transcription Factor Info
benzo(e)pyrene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	benzo(e)pyrene results in increased methylation of SLC6A3 intron			[75]
Regulation Mechanism				Transcription Factor Info
Benztropine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benztropine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction NDFIP1 protein results in decreased expression of SLC6A3 protein			[76]
Regulation Mechanism				Transcription Factor Info
bisindolylmaleimide I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisindolylmaleimide I inhibits the reaction Dopamine co-treated with SLC6A3 protein results in increased expression of FOS protein			[65]
Regulation Mechanism				Transcription Factor Info
bisphenol A	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC6A3 gene			[77]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol A results in decreased methylation of SLC6A3 gene			[77]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	bisphenol A results in increased expression of SLC6A3 protein			[49]
Regulation Mechanism				Transcription Factor Info
bisphenol S	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol S results in decreased methylation of SLC6A3 gene			[77]
Regulation Mechanism				Transcription Factor Info
Cadmium Chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased expression of SLC6A3 mRNA			[79]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC6A3 gene			[81]
Regulation Mechanism				Transcription Factor Info
Clozapine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 5' UTR affects the susceptibility to Clozapine			[82]
Regulation Mechanism				Transcription Factor Info
decamethrin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	decamethrin affects the activity of SLC6A3 protein			[35]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	decamethrin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[35]
Regulation Mechanism				Transcription Factor Info
deguelin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	deguelin results in decreased expression of SLC6A3 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
Dronabinol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dronabinol binds to SLC6A3 protein			[94]
Regulation Mechanism				Transcription Factor Info
Estradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol binds to ESR2 protein which results in increased expression of SLC6A3 mRNA			[95]
Regulation Mechanism				Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC6A3 gene			[77]
Regulation Mechanism				Transcription Factor Info
Ibogaine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ibogaine inhibits the reaction SLC6A3 protein mutant form results in decreased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ibogaine promotes the reaction SLC6A3 protein results in increased import of Dopamine			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Ibogaine results in increased expression of SLC6A3 protein			[78]
Regulation Mechanism				Transcription Factor Info
indatraline	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	indatraline inhibits the reaction SLC6A3 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
Ketamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[62]
Regulation Mechanism				Transcription Factor Info
Maneb	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene polymorphism affects the susceptibility to Maneb			[96]
Regulation Mechanism				Transcription Factor Info
Manganese	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	LRRK2 mutant form results in increased susceptibility to Manganese co-treated with SLC6A3 protein			[91]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Manganese affects the localization of SLC6A3 protein			[92]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 gene SNP affects the susceptibility to Manganese			[97]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A3 protein results in increased susceptibility to Manganese			[57]
Regulation Mechanism				Transcription Factor Info
Melitten	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the reaction Melitten results in increased localization of SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Melitten inhibits the reaction 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Melitten inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Melitten results in increased localization of SLC6A3 protein			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Melitten results in increased localization of SLC6A3 protein co-treated with RAB5A protein			[98]
Regulation Mechanism				Transcription Factor Info
Methapyrilene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methapyrilene results in increased methylation of SLC6A3 intron			[75]
Regulation Mechanism				Transcription Factor Info
Monensin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[58]
Regulation Mechanism				Transcription Factor Info
mono-(2-ethylhexyl)phthalate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	mono-(2-ethylhexyl)phthalate results in decreased expression of SLC6A3 mRNA			[104]
Regulation Mechanism				Transcription Factor Info
monomethylpropion	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	monomethylpropion results in decreased expression of SLC6A3 protein			[105]
Regulation Mechanism				Transcription Factor Info
Naltrexone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene polymorphism affects the susceptibility to Naltrexone			[106]
Regulation Mechanism				Transcription Factor Info
N-Methyl-3,4-methylenedioxyamphetamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A3 protein results in increased import of Biogenic Monoamines analog			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A3 protein results in increased import of Fluorescent Dyes			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[58]
Regulation Mechanism				Transcription Factor Info
Nomifensine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nomifensine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Nomifensine results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
Norepinephrine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 protein promotes the reaction Norepinephrine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 protein results in increased uptake of Norepinephrine			[47]
Regulation Mechanism				Transcription Factor Info
nuciferine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nuciferine results in increased activity of SLC6A3 protein			[107]
Regulation Mechanism				Transcription Factor Info
Octopamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
Oxidopamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 protein results in increased susceptibility to Oxidopamine			[108]
Regulation Mechanism				Transcription Factor Info
para-methyl-4-methylaminorex	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	para-methyl-4-methylaminorex binds to SLC6A3 protein			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	para-methyl-4-methylaminorex inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	para-methyl-4-methylaminorex results in decreased activity of SLC6A3 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A3 protein results in increased uptake of para-methyl-4-methylaminorex			[64]
Regulation Mechanism				Transcription Factor Info
phenethylamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the reaction SLC6A3 protein results in increased transport of phenethylamine			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 protein promotes the reaction phenethylamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein results in increased transport of phenethylamine			[85]
Regulation Mechanism				Transcription Factor Info
picoxystrobin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	picoxystrobin results in decreased expression of SLC6A3 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
Piperidines	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Piperidines analog binds to SLC6A3 protein			[110]
Regulation Mechanism				Transcription Factor Info
pirinixic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pirinixic acid binds to and results in increased activity of PPARA protein which results in decreased expression of SLC6A3 mRNA			[111]
Regulation Mechanism				Transcription Factor Info
ponceau 4R	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with Tartrazine co-treated with ponceau 4R co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
pyrachlostrobin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pyrachlostrobin results in decreased expression of SLC6A3 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
Pyrilamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrilamine analog binds to and affects the activity of SLC6A3 protein			[112]
Regulation Mechanism				Transcription Factor Info
quinoline yellow	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with quinoline yellow co-treated with Allura Red AC Dye co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
Quinpirole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quinpirole affects the localization of SLC6A3 protein			[89]
Regulation Mechanism				Transcription Factor Info
Serotonin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 protein promotes the reaction Serotonin results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 protein results in increased uptake of Serotonin			[47]
Regulation Mechanism				Transcription Factor Info
Sodium Benzoate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with quinoline yellow co-treated with Allura Red AC Dye co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with Tartrazine co-treated with ponceau 4R co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
Staurosporine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SNCA protein affects the reaction Staurosporine results in increased activity of SLC6A3 protein			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Staurosporine results in increased activity of SLC6A3 protein			[48]
Regulation Mechanism				Transcription Factor Info
Sulpiride	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulpiride inhibits the reaction Dopamine affects the localization of SLC6A3 protein			[89]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sulpiride inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
Tartrazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene SNP affects the susceptibility to 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with azo rubin S co-treated with Tartrazine co-treated with ponceau 4R co-treated with Sodium Benzoate			[66]
Regulation Mechanism				Transcription Factor Info
Tetradecanoylphorbol Acetate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetradecanoylphorbol Acetate results in increased localization of SLC6A3 protein co-treated with EEA1 protein			[98]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tretinoin co-treated with Tetradecanoylphorbol Acetate results in increased expression of SLC6A3 protein			[113]
Regulation Mechanism				Transcription Factor Info
theaflavin-3,3'-digallate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	theaflavin-3,3'-digallate affects the expression of SLC6A3 mRNA			[114]
Regulation Mechanism				Transcription Factor Info
thifluzamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	thifluzamide results in decreased expression of SLC6A3 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
Thimerosal	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Thimerosal co-treated with Aluminum Hydroxide results in increased expression of SLC6A3 protein			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Thimerosal results in increased expression of SLC6A3 protein			[68]
Regulation Mechanism				Transcription Factor Info
Tretinoin	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aluminum Hydroxide promotes the reaction BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Coconut Oil inhibits the reaction Aluminum Hydroxide promotes the reaction BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Coconut Oil inhibits the reaction BDNF protein co-treated with Tretinoin results in decreased expression of SLC6A3 protein			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Tretinoin co-treated with Tetradecanoylphorbol Acetate results in increased expression of SLC6A3 protein			[113]
Regulation Mechanism				Transcription Factor Info
tryptamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A3 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
Tyramine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A3 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Methylphenidate inhibits the reaction SLC6A3 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A3 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[90]
Regulation Mechanism				Transcription Factor Info
vanoxerine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	vanoxerine binds to SLC6A3 protein			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	vanoxerine inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	vanoxerine results in decreased activity of SLC6A3 protein which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium			[57]
Regulation Mechanism				Transcription Factor Info
Wortmannin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Wortmannin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[89]
Regulation Mechanism				Transcription Factor Info
Herbicide
Paraquat	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	MT2A protein inhibits the reaction Paraquat results in decreased expression of SLC6A3 mRNA			[109]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A3 gene polymorphism affects the susceptibility to Paraquat			[96]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Cocaine	24 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the transportation of Dopamine by SLC6A3			[1]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Cocaine inhibits the transportation of Dopamine by SLC6A3			[2], [3]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
DT Modulation3	Cocaine inhibits the transportation of Mazindol by SLC6A3			[4]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation4	Cocaine inhibits the transportation of RTI-55 by SLC6A3			[4], [5]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation5	Cocaine inhibits the activity of SLC6A3			[6], [7]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation6	Cocaine inhibits the activity of SLC6A3			[2], [3]
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
Mazindol	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mazindol inhibits the transportation of Mazindol by SLC6A3			[4]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Mazindol inhibits the transportation of RTI-55 by SLC6A3			[4]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation3	Mazindol inhibits the transportation of WIN-35428 by SLC6A3			[8]
Affected Drug/Substrate	WIN-35428	Modulation Type	Inhibition
Cell System	Chinese hamster ovary (CHO) cells-DAT1
DT Modulation4	Mazindol inhibits the activity of SLC6A3			[6]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation5	Mazindol inhibits the activity of SLC6A3			[9], [10], [11]
Cell System	Chinese hamster ovary (CHO) cells-DAT1
Duloxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Duloxetine inhibits the transportation of Dopamine by SLC6A3			[12]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Duloxetine inhibits the transportation of WIN-35428 by SLC6A3			[15]
Affected Drug/Substrate	WIN-35428	Modulation Type	Inhibition
DT Modulation3	Duloxetine inhibits the activity of SLC6A3			[16], [17], [18], [19]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Reboxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Reboxetine inhibits the transportation of Dopamine by SLC6A3			[12]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Reboxetine inhibits the transportation of WIN-35428 by SLC6A3			[14]
Affected Drug/Substrate	WIN-35428	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation3	Reboxetine inhibits the activity of SLC6A3			[18]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Modafinil	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Modafinil inhibits the transportation of Uridine by SLC6A3			[13]
Affected Drug/Substrate	Uridine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
DT Modulation2	Modafinil inhibits the activity of SLC6A3			[2]
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
DT Modulation3	Modafinil modulates the activity of SLC6A3			[20]
Fluoxetine	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluoxetine inhibits the transportation of Dopamine by SLC6A3			[1], [21], [22]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Fluoxetine inhibits the activity of SLC6A3			[24], [25], [26]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Venlafaxine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Venlafaxine inhibits the transportation of Dopamine by SLC6A3			[1], [22]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Venlafaxine inhibits the activity of SLC6A3			[19], [26]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Methylphenidate	16 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylphenidate inhibits the activity of SLC6A3			[23]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
DT Modulation2	Methylphenidate blocks the activity of SLC6A3			[27]
Decitabine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Decitabine inhibits DNA methyltransferase, which then enhances the expression of SLC6A3 via downregulating the promoter hypermethylation level			[28]
Cell System	Human dopaminergic neuroblastoma cell line (SH-SY-5Y)
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic acid inhibits histone deacetylase, which then enhances the expression of SLC6A3 via increasing the histone acethylation level			[29]
Cell System	Model organism in vivo (rat)
4-Fluoroamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 3.7 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
4-Fluoromethamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoromethamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 7.7 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
alpha-Pyrrolidinopentiophenone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	alpha-Pyrrolidinopentiophenone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.04 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Amphetamine	13 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.3 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Ephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 46 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Methamphetamine	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.1 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Citalopram	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the transportation of Dopamine by SLC6A3			[31]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
Amitriptyline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitriptyline inhibits the transportation of Dopamine by SLC6A3			[1]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Dextroamphetamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dextroamphetamine inhibits the transportation of Dopamine by SLC6A3			[1]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Dopamine	62 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dopamine inhibits the activity of SLC6A3			[32]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Bupropion	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bupropion inhibits the activity of SLC6A3			[7]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Dexmethylphenidate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dexmethylphenidate inhibits the activity of SLC6A3			[33], [34]
Cell System	N2A neuroblastoma cells-DAT1
Milnacipran	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Milnacipran inhibits the activity of SLC6A3			[18]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Desvenlafaxine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desvenlafaxine inhibits the activity of SLC6A3			[19]
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Armodafinil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Armodafinil inhibits the activity of SLC6A3			[2]
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1
Permethrin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Permethrin affects the activity of SLC6A3			[35]
Calcitriol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Calcitriol increases the expression of SLC6A3			[36]
Testosterone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Testosterone increases the expression of SLC6A3			[36]
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carbamazepine affects the expression of SLC6A3			[37]
Vorinostat	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vorinostat increases the expression of SLC6A3			[38]
Ioflupane I-123	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ioflupane I-123 modulates the activity of SLC6A3			[40]
Altropane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Altropane inhibits the activity of SLC6A3			[41]
Paroxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Paroxetine inhibits the activity of SLC6A3			[42]
Haloperidol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Haloperidol inhibits the activity of SLC6A3			[43]
Clomipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clomipramine inhibits the activity of SLC6A3			[44]
Dimethyl fumarate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dimethyl fumarate induces the activity of SLC6A3			[45]
Drug Marketed but not Approved by US FDA
Rotenone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rotenone inhibits the expression of SLC6A3			[39]
Drug in Phase 2/3 Trial
Sodium butyrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium butyrate inhibits histone deacetylase, which then enhances the expression of SLC6A3 via increasing the histone acethylation level			[28]
Cell System	Human embryonic kidney 293 cells (HEK293)
Drug in Phase 3 Trial
Dasotraline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dasotraline inhibits the activity of SLC6A3			[51]
Amitifadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitifadine inhibits the activity of SLC6A3			[53], [54], [55]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A increases the expression of SLC6A3			[49]
Amfetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amfetamine inhibits the activity of SLC6A3			[52]
DOV 21947	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	DOV 21947 inhibits the activity of SLC6A3			[56]
Drug in Phase 1 Trial
Butyrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Butyrate increases the expression of SLC6A3			[47]
Drug in Preclinical Test
AM-2282	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	AM-2282 increases the activity of SLC6A3			[48]
Investigative Drug
3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.11 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.53 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Methcathinone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methcathinone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 2.4 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Methylenedioxypyrovalerone (MDPV)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.05 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Pyrovalerone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrovalerone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.07 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Drug Withdrawn
Naphyrone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Naphyrone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.22 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Natural Product
4-Fluoroephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 163 microM)			[30]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-DAT1
Deguelin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Deguelin inhibits the expression of SLC6A3			[39]
Caffeine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A3 gene polymorphism affects the susceptibility to Caffeine			[80]
Regulation Mechanism				Transcription Factor Info
Curcumin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Curcumin inhibits the reaction 1-Methyl-4-phenylpyridinium results in decreased expression of SLC6A3 protein			[50]
Regulation Mechanism				Transcription Factor Info
Environmental toxicant
Zinc	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zinc inhibits the activity of SLC6A3			[46]
Pesticide/Insecticide
DT Modulation1	Permethrin affects the activity of SLC6A3 protein			[35]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Permethrin inhibits the reaction SLC6A3 protein results in increased uptake of Dopamine			[35]
Regulation Mechanism				Transcription Factor Info
Decamethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Decamethrin affects the activity of SLC6A3			[35]
Health and Environmental Toxicant
1-methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-methyl-4-phenylpyridinium inhibits the expression of SLC6A3			[50]

References
1	An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
2	Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. J Med Chem. 2016 Dec 8;59(23):10676-10691.
3	Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
4	Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
5	Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
6	Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
7	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
8	1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. J Med Chem. 2009 Sep 24;52(18):5703-11.
9	Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5029-32.
10	Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J Med Chem. 2010 Jun 10;53(11):4511-21.
11	Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). J Med Chem. 2011 Oct 13;54(19):6824-31.
12	Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
13	Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem. 2014 Feb 13;57(3):1000-13.
14	[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
15	Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6.
16	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
17	N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
18	A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1456-61.
19	Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
20	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
21	Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
22	Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
23	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
24	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
25	Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
26	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3--Oxyazetidine. ACS Med Chem Lett. 2014 Jul 10;5(9):999-1004.
27	Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
28	The correlation between DNA methylation and transcriptional expression of human dopamine transporter in cell lines. Neurosci Lett. 2018 Jan 1;662:91-97.
29	Effects of atomoxetine on hyper-locomotive activity of the prenatally valproate-exposed rat offspring. Biomol Ther (Seoul). 2014 Sep;22(5):406-13.
30	Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
31	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
32	Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
33	Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling. Bioorg Med Chem. 2011 Jan 1;19(1):504-12.
34	Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (+-)-threo-Methylphenidate. ACS Med Chem Lett. 2012 May 10;3(5):378-382.
35	Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97.
36	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
37	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
38	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
39	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615.
40	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
41	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
42	Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem. 2005 Sep 22;48(19):6023-34.
43	Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
44	Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
45	The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-kB/Nuclear Transcription Factor Related to NF-E2. Antioxid Redox Signal. 2017 Sep 10;27(8):453-471.
46	Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol. 2006 Aug;70(2):542-8.
47	Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem. 2007 Apr;101(2):377-88.
48	The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci. 2008 Dec;28(12):2459-73.
49	Adverse effects of bisphenol A (BPA) on the dopamine system in two distinct cell models and corpus striatum of the Sprague-Dawley rat. J Toxicol Environ Health A. 2016;79(20):912-24.
50	Curcumin Protects an SH-SY5Y Cell Model of Parkinson's Disease Against Toxic Injury by Regulating HSP90. Cell Physiol Biochem. 2018;51(2):681-691.
51	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
52	Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment. CNS Drugs. 2010 Sep;24(9):721-8.
53	Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
54	1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
55	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
56	1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors. Bioorg Med Chem. 2011 Jun 1;19(11):3451-61.
57	The role of dopamine transporter in selective toxicity of manganese and rotenone. Toxicology. 2008;244(2-3):249-56.
58	The psychostimulant ()-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282-291.
59	Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport. 2002;13(10):1279-83.
60	Dopamine transport function is elevated in cocaine users. J Neurochem. 2002;81(2):292-300.
61	Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol In Vitro. 2017;45(Pt 1):60-71.
62	Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT). Toxicology. 2019;422:69-75.
63	Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins. Eur J Pharmacol. 2011;650(2-3):501-10.
64	Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100.
65	Dopamine transporter-dependent induction of C-Fos in HEK cells. Synapse. 2002;45(1):52-65.
66	The role of histamine degradation gene polymorphisms in moderating the effects of food additives on children's ADHD symptoms. Am J Psychiatry. 2010;167(9):1108-15.
67	Evaluation of possible neuroprotective effects of virgin coconut oil on aluminum-induced neurotoxicity in an in vitro Alzheimer's disease model. J Appl Toxicol. 2024;44(4):609-622.
68	Evaluation of the toxic effects of thimerosal and/or aluminum hydroxide in SH-SY5Y cell line. Hum Exp Toxicol. 2022;41:9603271221136206.
69	Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci. 2008;28(28):7040-6.
70	Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse. 2009;35(3):161-77.
71	Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005;30(3):602-9.
72	Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation. Neuroscience. 2001;107(2):265-74.
73	DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response. Arch Toxicol. 2018;92(5):1785-1795.
74	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
75	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
76	Protective effects of Ndfip1 on MPP(+)-induced apoptosis in MES23.5 cells and its underlying mechanisms. Exp Neurol. 2015;273:215-24.
77	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
78	Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016;291(42):22053-22062.
79	Evaluation of cadmium-induced transcriptome alterations by three color cDNA labeling microarray analysis on a T-cell line. Toxicology. 2002;178(2):135-60.
80	Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans. J Neurosci. 2014;34(2):566-73.
81	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
82	Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1026-32.
83	Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. Synapse. 1997;27(4):347-56.
84	Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513.
85	Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005;313(3):983-94.
86	Dopamine transporter mRNA in autopsy studies of chronic cocaine users. Brain Res Mol Brain Res. 1999;73(1-2):181-5.
87	Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. Neuroreport. 2005;16(13):1489-93.
88	The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome. Genomics. 1995;30(3):459-63.
89	The role of the dopamine transporter in dopamine-induced DNA damage. Brain Pathol. 2011;21(3):237-48.
90	Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007;321(1):116-27.
91	Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity. Neurotoxicology. 2013;37:100-7.
92	The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells. Neurotoxicology. 2013;35:121-8.
93	Does acetaldehyde mediate ethanol action in the central nervous system?. Alcohol Clin Exp Res. 2001;25(11):1570-5.
94	Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of invivo assays in mice. Neuropharmacology. 2016;110(Pt A):143-153.
95	Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem. 2010;285(29):22059-66.
96	Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect. 2009;117(6):964-9.
97	Interaction between manganese and SLC6A3 genetic polymorphisms in relation to dyslexia. Neurotoxicology. 2022;92:102-109.
98	Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells. Eur J Pharmacol. 2012;690(1-3):13-21.
99	Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol. 2007;17(1):46-52.
100	Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry. 2003;160(9):1699-701.
101	Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 2003;3(4):242-7.
102	Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000;20(20):7838-45.
103	Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics. 2004;4(2):83-92.
104	Alteration of the N(6)-methyladenosine epitranscriptomic profile in synthetic phthalate-treated human induced pluripotent stem cell-derived endothelial cells. Epigenomics. 2022;14(19):1139-1155.
105	Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18(20):8417-22.
106	Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. Alcohol Alcohol. 2008;43(5):516-22.
107	In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One. 2016;11(3):e0150602.
108	Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism. Toxicol In Vitro. 2021;76:105210.
109	The effects of metallothionein in paraquat-induced Parkinson disease model of zebrafish. Int J Neurosci. 2023;133(8):822-833.
110	Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites. Bioorg Med Chem. 2002;10(12):4091-102.
111	Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009;4(8):e6796.
112	GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J Med Chem. 2002;45(8):1577-84.
113	The mixture of "ecstasy" and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations. Arch Toxicol. 2014;88(2):455-73.
114	Theaflavin 3, 3'-Digallate Delays Ovarian Aging by Improving Oocyte Quality and Regulating Granulosa Cell Function. Oxid Med Cell Longev. 2021;2021:7064179.
115	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
116	Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2000;1(2):241-51.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence